Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the ...

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.

As I prepared for my appointment, the hospital asked me to sign its registration forms and to sign up for MyChart. In the ...

White House planned shift of research funding from universities to industry risks creating a drought in basic research, ...

A jury awarded $6 million in damages to scientist David Sabatini, whose career imploded after he was accused by a much younger colleague of inappropriate sexual conduct in his lab.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Ahead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most significant news ...

The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared ...

Working conditions are the larger problem. Burnout, chronic understaffing, and high turnover are among the most consistent ...

In mental health care, I encountered people who believed that medication changed who they were. They didn’t mean the common ...